Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TBC-M4
- Development stage
- Phase 1
- Lead developer
- Therion Biologics
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
TBC-M4 is a recombinant modified vaccinia Ankara (MVA) vaccine candidate for HIV prevention. It contains HIV-1 subtype C genes including env, gag, reverse transcriptase (RT), rev, tat, and nef. The vaccine functions as an immunostimulant designed to induce both cellular and humoral immune responses against HIV-1.
02
Targets
Human immunodeficiency virus type 1 clade C antigens
Beyond the preview
Go deeper on TBC-M4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TBC-M4.